How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Delivery Device for Inhaled Nitric Oxide Therapy Market
- By Device Type: Portable Delivery Systems, Stationary Delivery Systems, Integrated Ventilator Delivery Systems, Standalone Delivery Modules
- By End User: Hospitals, Neonatal Intensive Care Units (NICU), Home Care Settings, Ambulatory Care Centers
- By Therapy Application: Pulmonary Hypertension Treatment, Acute Respiratory Distress Syndrome (ARDS), Persistent Pulmonary Hypertension of the Newborn (PPHN), Cardiac Surgery Support
- By Technology: Continuous Delivery Systems, Intermittent Delivery Systems, Automated Dose Control Systems
- By Product Feature: Real-time Monitoring and Feedback, Alarm and Safety Systems, Dose Titration Capability, Battery Operated Devices
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Portable Delivery Systems leads By Device Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the Delivery Device for Inhaled Nitric Oxide Therapy Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Mallinckrodt Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Vyaire Medical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →INO Therapeutics (a division of Mallinckrodt Pharmaceuticals)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bellerophon Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →SLE (Severe Lung Experts) Medical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Inomax (a brand by Mallinckrodt)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Praxis Precision Medicines
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Pulmonox Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Linde Healthcare
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Air Liquide Medical Systems
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Masimo Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Fisher & Paykel Healthcare
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Philips Respironics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →GE Healthcare
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Smiths Medical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Portable Delivery Systems56.2
- Stationary Delivery Systems14.9
- Integrated Ventilator Delivery Systems14.3
- Standalone Delivery Modules14.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Mallinckrodt Pharmaceuticals20.4
- Vyaire Medical19.7
- INO Therapeutics (a division of Mallinckrodt Pharmaceuticals)5.5
- Bellerophon Therapeutics8.0
- SLE (Severe Lung Experts) Medical8.7
- Inomax (a brand by Mallinckrodt)9.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.4
- Europe22.6
- Asia Pacific20.8
- Latin America12.9
- Middle East and Africa9.2
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Mallinckrodt Pharmaceuticals | 81 | 98 | 84 | 93 | 80 | 95 | 89 |
| Vyaire Medical | 91 | 79 | 81 | 73 | 73 | 90 | 81 |
| INO Therapeutics (a division of Mallinckrodt Pharmaceuticals) | 83 | 70 | 88 | 74 | 64 | 73 | 75 |
| Bellerophon Therapeutics | 80 | 78 | 61 | 75 | 68 | 77 | 73 |
| SLE (Severe Lung Experts) Medical | 75 | 65 | 57 | 70 | 58 | 62 | 65 |
| Inomax (a brand by Mallinckrodt) | 65 | 57 | 71 | 55 | 63 | 55 | 61 |
| Praxis Precision Medicines | 61 | 53 | 56 | 63 | 47 | 55 | 56 |
| Pulmonox Medical | 60 | 49 | 44 | 57 | 35 | 46 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Mallinckrodt Pharmaceuticals
- Vyaire Medical
- INO Therapeutics (a division of Mallinckrodt Pharmaceuticals)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Mallinckrodt Pharmaceuticals | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Vyaire Medical | ◐ | ◐ | ✓ | ✓ | − | ✓ |
| INO Therapeutics (a division of Mallinckrodt Pharmaceuticals) | ✓ | − | ✓ | ◐ | − | ◐ |
| Bellerophon Therapeutics | ✓ | ◐ | ◐ | ◐ | ◐ | ✓ |
| SLE (Severe Lung Experts) Medical | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Inomax (a brand by Mallinckrodt) | − | ◐ | ◐ | − | − | − |
| Praxis Precision Medicines | ◐ | ◐ | − | − | − | ◐ |
| Pulmonox Medical | − | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Challenger2
Strong scale, closing on the leaders.
Contender2
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Device Type in North America, then scale across Delivery Device for Inhaled Nitric Oxide Therapy Market — a $537M beachhead inside a $8.54B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Portable Delivery Systems
Best fit — highest urgency & budget in Device Type.
Stationary Delivery Systems
Strong fit — clear ROI and a fast path to value.
Integrated Ventilator Delivery Systems
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Device Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Therapy Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Device Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Delivery Device for Inhaled Nitric Oxide Therapy Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Delivery Device for Inhaled Nitric Oxide Therapy Market is a resilient opportunity — $5.71B by 2033, compounding at 4.5%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.5% CAGR
Demand compounds through 2033, outpacing GDP across Device Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Device Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Delivery Device for Inhaled Nitric Oxide Therapy Market — a $11.5B market by 2033. Plan: grow share from 8.7% to 16.1%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.7% | 16.1% | At risk |
| Revenue | $1.01B | $1.86B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 32.9% | 43.1% | Ahead |
| Customer retention | 86.9% | 96.3% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Device Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Device Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $249M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Device Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentOn track
Sales deck · value proposition
Win the Delivery Device for Inhaled Nitric Oxide Therapy Market conversation — a $2.82B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Device Type
Goal Grow share in Device Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Delivery Device for Inhaled Nitric Oxide Therapy Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Delivery Device for Inhaled Nitric Oxide Therapy Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Delivery Balloon Dilatation Catheter Market
Market size, share, segmentation and regional forecast.
$465M market · 2025 base year
View reportDelivered Dose Uniformity (DDU) Sampling Apparatus Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportDelay Myopia Deepening Product Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportDelafloxacin Meglumine Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportDehydroxy Pancreatin Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportDehydroquercetin (DHQ) Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportDehydronandrolone Acetate Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportDehydroepiandrosterone (DHEA) Supplement Market
Market size, share, segmentation and regional forecast.
$488M market · 2025 base year
View reportDehydration Monitoring Devices Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportCountertop Power Dental Flosser Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportPortable Power Dental Flosser Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportPower Dental Flosser Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy